HORIZONH2020
Innovation Acta SRL
- Country
- ITItaly
- Defence projects
- 0
- Projects, all programmes
- 28
- As coordinator
- 0
- EU contribution (CORDIS)
- EUR 5,595,766
- Active
- 2017 to 2025
Projects
28 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| AUREUSwAll teichoic acids as immUnogenic and conseRved altErnative targets for therapies versUs S. aureus | HORIZON | 2025 | Associated partner | EUR 0 |
| InFlaMeCounter-acting the pandemic potential of flaviviruses: addressing virus-host interactions and defense strategies to design new therapeutics against WNV and DENV | HORIZON | 2025 | Participant | EUR 250,000 |
| INSIDE:INSIGHTThe integration of technology with medical and healthcare education - a leadership program | HORIZON | 2025 | Associated partner | EUR 0 |
| SECRETExploring the therapeutic potential of perinatal cell SECRETomes | HORIZON | 2024 | Associated partner | EUR 0 |
| GLYCO-NGLYCOprotein N-glycosylation from non-life to eukaryotes: a Doctoral Network to expand the knowledge on a ubiquitous posttranslational modification of proteins | HORIZON | 2024 | Associated partner | EUR 0 |
| LIVERAIMA Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy | HORIZON | 2024 | Participant | EUR 499,555 |
| BactEradiXAdvanced nanomaterials to target genomic and Z-DNA for bacterial biofilm eradication | HORIZON | 2024 | Participant | EUR 303,313 |
| CohesiNetCohesin and its regulators: from chromosome dynamics and nuclear architecture to human diseases | HORIZON | 2023 | Associated partner | EUR 0 |
| GlyCanDrugA training network on the design of precision therapeutics that target key glycan motifs implicated in cancer | HORIZON | 2023 | Associated partner | EUR 0 |
| THRIVETUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS | HORIZON | 2023 | Participant | EUR 372,174 |
| GUIDE.MRDGUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD | HORIZON | 2023 | Participant | EUR 377,734 |
| B-specificB-specific: B-cell related gene and protein markers with prognostic and therapeutic value for CVD | HORIZON | 2023 | Participant | EUR 202,044 |
| exTraInnovative Applications of Extracorporeal Photopheresis in Solid Organ Transplantation | HORIZON | 2023 | Associated partner | EUR 0 |
| TOP-GUTTraining for Organoids modelling Physiology and Pathology in the human gastrointestinal tract | HORIZON | 2023 | Associated partner | EUR 0 |
| IMMUTOLADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED DISEASES | HORIZON | 2023 | Participant | EUR 375,729 |
| PROTOPROTO - Advanced PeRsOnalized Therapies for Osteoarthritis – TACKLING INFLAMMATION TO IMPROVE PATIENT OUTCOMES | HORIZON | 2023 | Participant | EUR 303,364 |
| TOLERATEAn integrated approach to restore tolerance in autoimmune disease | HORIZON | 2022 | Associated partner | EUR 0 |
| geneTIGAGene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology | HORIZON | 2022 | Participant | EUR 598,631 |
| T-FITNESSFINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS | HORIZON | 2022 | Participant | EUR 234,739 |
| LiverScreenScreening for liver fibrosis - population-based study across European countries | H2020 | 2020 | Participant | EUR 226,004 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.